[HTML][HTML] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - … journal of oncology, 2021 - spandidos-publications.com
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer
J He, Z Huang, L Han, Y Gong… - International Journal of …, 2021 - search.ebscohost.com
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong, C Xie - International Journal of …, 2021 - europepmc.org
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
[HTML][HTML] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - … Journal of Oncology, 2021 - spandidos-publications.com
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer
J He, Z Huang, L Han, Y Gong, C Xie - International Journal of …, 2021 - go.gale.com
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - International journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
[PDF][PDF] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J HE, Z HUANG, L HAN… - INTERNATIONAL …, 2021 - pdfs.semanticscholar.org
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer
J He, Z Huang, L Han - International Journal of Oncology, 2021 - search.proquest.com
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J HE, Z HUANG, L HAN, YAN GONG… - INTERNATIONAL …, 2021 - ingentaconnect.com
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1stline treatments for patients with advanced …
(TKIs) is a standard modality of the 1stline treatments for patients with advanced …
[HTML][HTML] Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer
J He, Z Huang, L Han, Y Gong, C Xie - International Journal of …, 2021 - ncbi.nlm.nih.gov
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR …